M-M-R II

Active immunization for the prevention of MMR in individuals ≥12 mth of age.

IM/SC Single dose of 0.5 mL. Administer 1st dose at 12-15 mth of age, then 2nd dose at 4-6 yr of age. 2nd dose may be administered prior to 4 yr of age, provided that there is a min interval of 1 mth between doses. Childn who received an initial dose prior to their 1st birthday should receive additional doses at 12-15 mth of age & at 4-6 yr of age to complete the vaccination series. For post-exposure prophylaxis of measles, administer a dose w/in 72 hr after exposure.

Hypersensitivity to any component of the vaccine (including gelatin). Hypersensitivity reaction following administration of a previous dose of M-M-R II vaccine or any other MMR-containing vaccine. History of anaphylaxis to neomycin. Immunodeficient or immunosuppressed individuals due to disease or medical therapy. Individuals w/ active febrile illness w/ fever >101.3°F (>38.5°C). Individuals w/ active untreated TB. Individuals who are pregnant or who are planning on becoming pregnant w/in the next mth.

Risk of fever & associated febrile seizures in the 1st 2 wk following immunization. Individuals w/ history of anaphylactic, anaphylactoid, or other immediate reactions subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after vaccination. Reports of transient thrombocytopenia w/in 4-6 wk following vaccination. Defer vaccination in individuals w/ family history of congenital or hereditary immunodeficiency until immunocompetence is confirmed. Should not be given concurrently w/ Ig & other blood products. Consider benefits of breastfeeding along w/ mother's clinical need for M-M-R II & any potential adverse effects on the breastfed child. Not approved for individuals <12 mth of age.

Panniculitis, atypical measles, fever, headache, dizziness, malaise, irritability; vasculitis; pancreatitis, diarrhea, vomiting, parotitis, nausea; thrombocytopenia, purpura, regional lymphadenopathy, leukocytosis; anaphylaxis, anaphylactoid reactions, angioedema, bronchial spasm; arthritis, arthralgia, myalgia; encephalitis, encephalopathy, measles inclusion body encephalitis, subacute sclerosing panencephalitis, Guillain-Barré syndrome, acute disseminated encephalomyelitis, transverse myelitis, febrile convulsions, afebrile convulsions or seizures, ataxia, polyneuritis, polyneuropathy, ocular palsies, paresthesia, syncope; pneumonia, pneumonitis, sore throat, cough, rhinitis; SJS, acute hemorrhagic edema of infancy, Henoch-Schönlein purpura, erythema multiforme, urticaria, rash, measles-like rash, pruritus, inj site reactions; nerve deafness, otitis media; retinitis, optic neuritis, papillitis, conjunctivitis; epididymitis, orchitis.

Risk of disseminated disease due to measles vaccine in individuals on immunosuppressive drugs, including high-dose corticosteroids. Concurrent administration w/ Ig & other blood products may interfere w/ expected immune response. May result in temporary depression of tuberculin skin sensitivity, therefore tuberculin skin test w/ tuberculin purified protein derivative should be administered before, simultaneously w/, or at least 4-6 wk after vaccination w/ M-M-R II vaccine. Can be administered concurrently w/ other live viral vaccines; otherwise, administer M-M-R II vaccine 1 mth before or 1 mth after administration of other live viral vaccines to avoid potential for immune interference.

Vaccines, Antisera & Immunologicals

J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.

P₁S₁S₃, A